Table 1 Features of published cases of hematological malignancies post-germ cell tumor
From: Three distinct hematological malignancies from a single germ cell tumor: a case report
| Patient age (49) | Median | 23 years | |
| Range | 11–35 years | ||
| Patient sex (63) | Exclusively male | ||
| Anatomic location of prior GCT (75) | Exclusively mediastinal | ||
| Histology of prior GCT (24) | Variable and often mixed, including immature teratoma, yolk-sac tumour, undifferentiated histologies | ||
| Frequency of specific karyotypic abnormalities in hematological malignancy (40) | Presence of i(12p) | 68% | |
| Presence of + 8 | 29% | ||
| Complex karyotype (≥ 3 structural abnormalities) | 48% | ||
| Type of hematological malignancy (74) | AML | 57% | |
| Histiocytic disorder | 10% | ||
| MDS (with megakaryocytic dysplasia) | 11% | ||
| Mast cell leukemia | 3% | ||
| ALL | 4% | ||
| Acute undifferentiated leukemia | 5% | ||
| MPN | 7% | ||
| Other | 4% | ||
| Morphological subtype of AML (where reported) (33) | M2 (Myeloblastic with maturation) | 9% | |
| M3 (Promyelocytic) | 3% | ||
| M4 (Myelomonocytic) | 24% | ||
| M5 (Monocytic) | 9% | ||
| M6 (Erythroblastic) | 6% | ||
| M7 (Megakaryoblastic) | 48% | ||
| Time from GCT diagnosis to hematological malignancy (51) | Median | 4 months | |
| Range | 0–47 months | ||
| Survival following GCT diagnosis (35) | Median | 5 weeks | |
| Maximum | 44 weeks | ||
